With the emergence of targeted therapies such as the third-generation EGFR-TKIs and the second-generation ALK-TKIs, as well as the rise of immunotherapy, the treatment pattern of lung cancer has undergone revolutionary changes. This evidence concerns the gene EGFR and lung cancer.